{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008122","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.301619+00:00","generated_at":"2026-06-18T02:13:59.357234+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adicet Bio Q4 2022 net loss $29.9M; cash $257.7M; ADI-001 ORR 75%","bullets":["Q4 net loss $29.9M ($0.72 per share) vs $15.8M in Q4 2021; FY net loss $69.8M.","Cash and equivalents $257.7M at Dec 31, 2022; expected runway into H1 2025.","R&D expenses Q4 $25.0M, up 70% YoY; G&A $6.6M, flat.","ADI-001 Phase 1 data: 75% ORR, 69% CR across doses; pivotal study plan in Q2 2023.","IND for ADI-925 (CAd gamma delta T cell) expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008122","json":"https://secwatch.observer/filing/0000950170-23-008122.json","markdown":"https://secwatch.observer/filing/0000950170-23-008122.md","text":"https://secwatch.observer/filing/0000950170-23-008122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023008122/0000950170-23-008122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023008122/acet-20230315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:13:59.357234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"266e33bfb22f92c6b110253e0067c43cadeacf8a","claim":"Adicet Bio, Inc. reported for the fourth quarter and year ended December 31, 2022 results: net income Net loss for the three months ended December 31, 2022 was $29.9 million, EPS a net loss of $0.72 per basic and diluted share.","evidence_excerpt":"Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023008122/0000950170-23-008122-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the fourth quarter and year ended December 31, 2022"},{"label":"Net income","value":"Net loss for the three months ended December 31, 2022 was $29.9 million"},{"label":"EPS","value":"a net loss of $0.72 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}